The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 08, 2024

Filed:

Apr. 03, 2019
Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Li-Sheng Lu, Mountain View, CA (US);

Mark J. Selby, San Francisco, CA (US);

Alan J. Korman, Piedmont, CA (US);

Shrikant Deshpande, Fremont, CA (US);

Mohan Srinivasan, Cupertino, CA (US);

Jun Zhang, Pleasanton, CA (US);

Haichun Huang, Fremont, CA (US);

Guodong Chen, East Brunswick, NJ (US);

Richard Y. Huang, Bridgewater, NJ (US);

Ekaterina Deyanova, Lawrenceville, NJ (US);

Assignee:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 39/39541 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/74 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01);
Abstract

This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.


Find Patent Forward Citations

Loading…